IDYA
Ideaya Biosciences Inc

1,306
Mkt Cap
$2.91B
Volume
934,839.00
52W High
$39.28
52W Low
$13.45
PE Ratio
-25.47
IDYA Fundamentals
Price
$35.08
Prev Close
$33.19
Open
$33.35
50D MA
$33.96
Beta
1.17
Avg. Volume
853,708.30
EPS (Annual)
-$1.28
P/B
2.85
Rev/Employee
$1.51M
$2,447.46
Loading...
Loading...
News
all
press releases
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Day One's stock surges 66% after Servier agrees to acquire it for $21.50 per share in a $2.5B deal, adding brain tumor drug Ojemda and oncology pipeline assets.
Zacks·8h ago
News Placeholder
More News
News Placeholder
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update IDEAYA...
PR Newswire·12h ago
News Placeholder
Fisher Asset Management LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. $IDYA
Fisher Asset Management LLC cut its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 6.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned...
MarketBeat·6d ago
News Placeholder
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up on Insider Buying Activity
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up After Insider Buying Activity...
MarketBeat·6d ago
News Placeholder
Insider Buying: IDEAYA Biosciences (NASDAQ:IDYA) Director Buys 50,000 Shares of Stock
IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) Director Jeffrey Stein purchased 50,000 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were purchased at...
MarketBeat·7d ago
News Placeholder
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYAs First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with...
Business Wire·10d ago
News Placeholder
Fifth Lane Capital LP Invests $932,000 in IDEAYA Biosciences, Inc. $IDYA
Fifth Lane Capital LP acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange...
MarketBeat·10d ago
News Placeholder
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN...
PR Newswire·10d ago
News Placeholder
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of...
PR Newswire·12d ago
News Placeholder
IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch
IDEAYA Biosciences (NASDAQ:IDYA) outlined upcoming clinical milestones for its precision oncology pipeline, emphasizing an imminent top-line readout in first-line metastatic uveal melanoma (MUM...
MarketBeat·14d ago
<
1
2
...
>

Latest IDYA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.